Titan Medical (NASDAQ:TMDI) vs. Liquidia Technologies (NASDAQ:LQDA) Head-To-Head Comparison
Titan Medical (NASDAQ:TMDI) and Liquidia Technologies (NASDAQ:LQDA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
Earnings & Valuation
This table compares Titan Medical and Liquidia Technologies’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Titan Medical||N/A||N/A||-$22.64 million||($1.36)||-0.51|
|Liquidia Technologies||$2.71 million||24.83||-$53.14 million||($7.51)||-0.48|
Risk & Volatility
Titan Medical has a beta of 4.61, meaning that its share price is 361% more volatile than the S&P 500. Comparatively, Liquidia Technologies has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Titan Medical and Liquidia Technologies, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Titan Medical presently has a consensus price target of $6.67, indicating a potential upside of 866.18%. Liquidia Technologies has a consensus price target of $50.00, indicating a potential upside of 1,285.04%. Given Liquidia Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Liquidia Technologies is more favorable than Titan Medical.
This table compares Titan Medical and Liquidia Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
8.6% of Titan Medical shares are owned by institutional investors. Comparatively, 58.8% of Liquidia Technologies shares are owned by institutional investors. 4.3% of Liquidia Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Liquidia Technologies beats Titan Medical on 7 of the 12 factors compared between the two stocks.
About Titan Medical
Titan Medical Inc., a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during MIS procedures. The SPORT Surgical System enables surgeons to perform surgical procedures for gynecologic, urologic, colorectal, and general abdominal indications. Titan Medical Inc. is headquartered in Toronto, Canada.
About Liquidia Technologies
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase 1 clinical trials for the treatment of local post-operative pain. It has collaboration agreements with GlaxoSmithKline plc and the University of North Carolina. Liquidia Technologies, Inc. was founded in 2004 and is headquartered in Morrisville, North Carolina.
Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.